Who are Anti R-IL2 + Cyclosporine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexamethasone Azathioprine Pulse therapy, Cyclophosphamide, Azathioprine,prednisone,methylprednisolone, ATG+mycophénolate mofétil+tacrolimus, CsA+MMF+CS, Kidney transplant maintenance immunosuppression, Zenapax®, CellCept® and prednisolone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-r-il2-cyclosporine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti R-IL2 + Cyclosporine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti R-IL2 + Cyclosporine (Anti R-IL2 + Cyclosporine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology / Transplantation.

phase 3 Immunosuppressive combination therapy IL-2 receptor (CD25) and calcineurin Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Anti R-IL2 + Cyclosporine (Anti R-IL2 + Cyclosporine) — University Hospital, Brest. Anti-IL-2 receptor antibody combined with cyclosporine suppresses T-cell activation and proliferation to prevent organ rejection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti R-IL2 + Cyclosporine TARGET	Anti R-IL2 + Cyclosporine	University Hospital, Brest	phase 3	Immunosuppressive combination therapy	IL-2 receptor (CD25) and calcineurin
Dexamethasone Azathioprine Pulse therapy	Dexamethasone Azathioprine Pulse therapy	Jinnah Postgraduate Medical Centre	marketed	Immunosuppressive combination therapy	Glucocorticoid receptor (dexamethasone); inosine monophosphate dehydrogenase (azathioprine)
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Assistance Publique - Hôpitaux de Paris	marketed	Immunosuppressive combination therapy
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
CsA+MMF+CS	CsA+MMF+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)
Kidney transplant maintenance immunosuppression	Kidney transplant maintenance immunosuppression	Imperial College Healthcare NHS Trust	marketed	Immunosuppressive combination therapy
Zenapax®, CellCept® and prednisolone	Zenapax®, CellCept® and prednisolone	University of Oslo School of Pharmacy	marketed	Immunosuppressive combination therapy	IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

University Hospital, Brest · 2 drugs in this class
Pfizer · 2 drugs in this class
Fundação Pró Rim · 2 drugs in this class
Haukeland University Hospital · 1 drug in this class
Imperial College Healthcare NHS Trust · 1 drug in this class
Jinnah Postgraduate Medical Centre · 1 drug in this class
Novartis · 1 drug in this class
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class
University Hospital Freiburg · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti R-IL2 + Cyclosporine — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-r-il2-cyclosporine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab